Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain

Abstract

The p53 tumor suppressor protein induces apoptosis through a mechanism that may involve the transcriptional activation of cellular genes, including the PIG3 gene. A p53 protein lacking the proline-rich region (p53Δ62-91) induces many p53-responsive genes but not PIG3. In parallel, this mutant induces growth arrest but not apoptosis. We show here that the replacement of the N-terminal (amino acids 1–80) or C-terminal (amino acids 344–393) domains of p53 with heterologous domains does not interfere with transcription from the PIG3 promoter, but these chimeras still require the proline-rich region for PIG3 activation. The p53-homolog p73β also activated the PIG3 promoter, but in contrast to p53, the proline-rich domain of p73β (residues 81–113) was dispensable to induce the PIG3 promoter. Some tumor-derived p53-mutants, especially M246I, retained the ability to activate transcription of mdm2 but specifically failed to induce the PIG3 promoter, thus resembling p53Δ62-91. Further, p53Δ62-91 and p53M246I were defective for induction of apoptosis. Finally, p53Δ62-91 and p53M246I both showed reduced binding to the DNA of the PIG3 promoter and also to the DNA of the mdm2 and p21 promoters in vitro. Correspondingly, at low expression levels, p53Δ62-91 and p53M246I poorly activated the mdm2 promoter when compared to wild type p53. Our results suggest that the proline-rich domain of p53 affects the ability of the central domain to bind DNA. Moreover, some tumor-derived mutations within the central DNA binding domain of p53 mimic the loss of the proline-rich domain.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Agami R, Blandino G, Oren M and Shaul Y . 1999 Nature 399: 809–813

  • Brachmann RK, Yu K, Eby Y, Pavletich NP and Boeke JD . 1998 EMBO J 17: 1847–1859

  • Chen X, Ko LJ, Jayaraman L and Prives C . 1996 Genes Dev 10: 2438–2451

  • Cho Y, Gorina S, Jeffrey PD and Pavletich NP . 1994 Science 265: 346–355

  • Dobbelstein M and Shenk T . 1996 J Virol 70: 6479–6485

  • Ellenberger TE, Brandl CJ, Struhl K and Harrison SC . 1992 Cell 71: 1223–1237

  • Freedman DA, Epstein CB, Roth JC and Levine AJ . 1997 Mol Med 3: 248–259

  • Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M and Wang JY . 1999 Nature 399: 806–809

  • Gu W and Roeder RG . 1997 Cell 90: 595–606

  • Harris CC . 1996 Carcinogenesis 17: 1187–1198

  • Hu JC, O'Shea EK, Kim PS and Sauer RT . 1990 Science 250: 1400–1403

  • Hupp TR, Meek DW, Midgley CA and Lane DP . 1992 Cell 71: 875–886

  • Jackson P, Bos E and Braithwaite AW . 1993 Oncogene 8: 589–597

  • Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M and Prives C . 1998 Genes Dev 12: 462–472

  • Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S and Prives C . 1997 Genes Dev 11: 558–570

  • Jost CA, Marin MC and Kaelin Jr WG . 1997 Nature 389: 191–194

  • Kaelin Jr WG . 1999 J Natl Cancer Inst 91: 594–598

  • Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F and Caput D . 1997 Cell 90: 809–819

  • König C, Roth J and Dobbelstein M . 1999 J Virol 73: 2253–2262

  • Levine AJ . 1997 Cell 88: 323–331

  • Meek DW . 1998 Cell Signal 10: 159–166

  • Minaguchi T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y and Nakamura Y . 1998 Cancer Res 58: 4585–4586

  • Nikolova PV, Henckel J, Lane DP and Fersht AR . 1998 Proc Natl Acad Sci USA 95: 14675–14680

  • Pietenpol JA, Tokino T, Thiagalingam S, el-Deiry WS, Kinzler KW and Vogelstein B . 1994 Proc Natl Acad Sci USA 91: 1998–2002

  • Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B . 1997 Nature 389: 300–305

  • Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA and Jacobs IJ . 1998 Lancet 352: 871–872

  • Roth J, König C, Wienzek S, Weigel S, Ristea S and Dobbelstein M . 1998 J Virol 72: 8510–8516

  • Ruaro EM, Collavin L, Del Sal G, Haffner R, Oren M, Levine AJ and Schneider C . 1997 Proc Natl Acad Sci USA 94: 4675–4680

  • Ryan KM and Vousden KH . 1998 Mol Cell Biol 18: 3692–3698

  • Sakamuro D, Sabbatini P, White E and Prendergast GC . 1997 Oncogene 15: 887–898

  • Sionov RV, Moallem E, Berger M, Kazaz A, Gerlitz O, Ben-Neriah Y, Oren M and Haupt Y . 1999 J Biol Chem 274: 8371–8374

  • Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G and Banks L . 1998 Nature 393: 229–234

  • Sun XF, Johannsson O, Hakansson S, Sellberg G, Nordenskjold B, Olsson H and Borg A . 1996 Oncogene 13: 407–411

  • Taylor JA, Li Y, He M, Mason T, Mettlin C, Vogler WJ, Maygarden S and Liu E . 1996 Cancer Res 56: 294–298

  • Thomas M, Kalita A, Labrecque S, Pim D, Banks L and Matlashewski G . 1999 Mol Cell Biol 19: 1092–1100

  • Unger T, Mietz JA, Scheffner M, Yee CL and Howley PM . 1993 Mol Cell Biol 13: 5186–5194

  • Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L and Debussche L . 1998 EMBO J 17: 4668–4679

  • Walker KK and Levine AJ . 1996 Proc Natl Acad Sci USA 93: 15335–15340

  • White E and Prives C . 1999 Nature 399: 734–735, 737

  • Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D and McKeon F . 1998 Mol Cell 2: 305–316

  • Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW and Vogelstein B . 1999 Proc Natl Acad Sci USA 96: 14517–14522

  • Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R and Kufe D . 1999 Nature 399: 814–817

  • Zhu J, Jiang J, Zhou W and Chen X . 1998 Cancer Res 58: 5061–5065

  • Zhu J, Jiang J, Zhou W, Zhu K and Chen X . 1999 Oncogene 18: 2149–2155

Download references

Acknowledgements

We thank H-D Klenk and R Arnold for their continuous support. We are indebted to B Vogelstein for the generous gift of plasmids and helpful advice. We also thank J Pietenpol and A Levine for plasmids; W Deppert and S Dehde for early passage H1299 cells. M Eilers, R Müller, M Beato and M Scheffner for helpful discussion. This work was supported by the German research foundation and the PE Kempkes foundation. A Contente received a fellowship from the European Union (Praxis XXI), and M Dobbelstein was a recipient of the Stipendium für Infektionsbiologie by the German cancer research center during this work.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roth, J., Koch, P., Contente, A. et al. Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain. Oncogene 19, 1834–1842 (2000). https://doi.org/10.1038/sj.onc.1203500

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203500

Keywords

This article is cited by

Search

Quick links